Verge Genomics' ALS Drug Fails Amid Shift to Partner Model
TL;DR Summary
Verge Genomics' only clinical-stage ALS drug has failed, prompting the company to shift its focus to a partnership model for its AI-driven discovery platform.
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
60%
60 → 24 words
Want the full story? Read the original article
Read on Endpoints News